Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

被引:104
作者
Belvederi Murri M. [1 ,2 ]
Guaglianone A. [1 ]
Bugliani M. [1 ]
Calcagno P. [1 ]
Respino M. [1 ]
Serafini G. [1 ]
Innamorati M. [3 ]
Pompili M. [3 ]
Amore M. [1 ]
机构
[1] Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Largo Rosanna Benzi, 10, Genoa
[2] Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London
[3] Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome
关键词
Clozapine; Risperidone; Olanzapine; Quetiapine; Aripiprazole;
D O I
10.1007/s40268-014-0078-0
中图分类号
学科分类号
摘要
Background: Neuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse reaction to antipsychotics. Second-generation antipsychotics (SGAs) were originally assumed to be free from the risk of causing NMS, however several cases of NMS induced by SGAs (SGA-NMS) have been reported.Objectives: The aim of this study was to systematically review available studies and case reports on SGA-NMS and compare the presentation of NMS induced by different SGAs.Data Sources: Citations were retrieved from PubMed up to November 2013, and from reference lists of relevant citations.Study Eligibility Criteria: Eligibility criteria included (a) primary studies reporting data on NMS, with at least 50 % of the sample receiving SGAs; or (b) case reports and case reviews reporting on NMS induced by SGA monotherapy, excluding those due to antipsychotic withdrawal.Study Appraisal and Synthesis Methods: A standardized method for data extraction and coding was developed for the analysis of eligible case reports.Results: Six primary studies and 186 individual cases of NMS induced by SGAs were included. Primary studies suggest that SGA-NMS is characterized by lower incidence, lower clinical severity, and less frequent lethal outcome than NMS induced by first-generation antipsychotics. Systematic analysis of case reports suggests that even the most recently marketed antipsychotics are not free from the risk of inducing NMS. Furthermore, clozapine-, aripiprazole- and amisulpride-induced NMS can present with atypical features more frequently than other SGA-NMS, i.e. displaying less intense extrapyramidal symptoms or high fever.Limitations: Case reports report non-systematic data, therefore analyses may be subject to bias.Conclusions and Implications of Key Findings: Clinicians should be aware that NMS is virtually associated with all antipsychotics, including those most recently marketed. Although apparently less severe than NMS induced by older antipsychotics, SGA-NMS still represent a relevant clinical issue. © 2015, The Author(s).
引用
收藏
页码:45 / 62
页数:17
相关论文
共 50 条
  • [21] Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
    Skonieczna-Zydecka, Karolina
    Loniewski, Igor
    Misera, Agata
    Stachowska, Ewa
    Maciejewska, Dominika
    Marlicz, Wojciech
    Galling, Britta
    PSYCHOPHARMACOLOGY, 2019, 236 (05) : 1491 - 1512
  • [22] Second-Generation Antipsychotics for the Treatment of Disruptive Behaviour Disorders in Children: A Systematic Review
    Pringsheim, Tamara
    Gorman, Daniel
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2012, 57 (12): : 722 - 727
  • [23] Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
    Giampaolo, Perna
    Alessandra, Alciati
    Raffaele, Balletta
    Elisa, Mingotto
    Giuseppina, Diaferia
    Paolo, Cavedini
    Maria, Nobile
    Daniela, Caldirola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (04)
  • [25] First- and Second-Generation Antipsychotics
    McEvoy, Joseph P.
    Zigman, Daniel
    Margolese, Howard C.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2010, 55 (03): : 144 - 149
  • [26] Second-generation antipsychotics for anxiety disorders
    Depping, Anna M.
    Komossa, Katja
    Kissling, Werner
    Leucht, Stefan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [27] Second-generation antipsychotics: a therapeutic downturn?
    Lewis, Shon
    PSYCHOLOGICAL MEDICINE, 2009, 39 (10) : 1603 - 1606
  • [28] Diabetes and second-generation (atypical) antipsychotics
    Chabroux, S.
    Haffen, E.
    Penfornis, A.
    ANNALES D ENDOCRINOLOGIE, 2009, 70 (04) : 202 - 210
  • [30] QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
    Mehrul Hasnain
    W. Victor R. Vieweg
    CNS Drugs, 2014, 28 : 887 - 920